Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$159.69 USD
+0.16 (0.10%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $159.69 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$159.69 USD
+0.16 (0.10%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $159.69 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
Zacks News
Kodiak (KOD) Q2 Earnings Miss, New Lead Candidate in Focus
by Zacks Equity Research
Kodiak (KOD) reports weaker-than-expected results in second-quarter 2023. The company also provides an update on the status of its pipeline after discontinuing the tarcocimab program.
Pfizer's (PFE) New Multiple Myeloma Drug Elrexfio Gets FDA Nod
by Zacks Equity Research
The FDA's accelerated approval of Pfizer's (PFE) new multiple myeloma drug Elrexfio/elranatamab is based on data from the pivotal phase II MagnetisMM-3 study.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is iShares Core Dividend Growth ETF (DGRO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DGRO
Boston Scientific's (BSX) POLARx System Gets FDA Approval
by Zacks Equity Research
Boston Scientific's (BSX) POLARx enables doctors to expand and modify the new POLARx catheter to match a patient's unique anatomy during an ablation treatment.
Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%
by Zacks Equity Research
Atreca (BCEL) suspends the development of only pipeline candidate, ATRC-101, in clinical evaluation, as part of its business restructuring efforts and cuts headcount by 40%. The stock falls 37%.
Pharma ETFs in Focus Post Q2 Earnings
by Sweta Killa
Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.
Johnson & Johnson (JNJ) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Catalyst (CPRX) Q2 Earnings & Sales Top, 2023 Outlook Raised
by Zacks Equity Research
Catalyst (CPRX) reports better-than-expected second-quarter 2023 results. Management raises full-year 2023 guidance.
Pharma Stock Roundup: LLY, BAYRY Post Q2 Results, NVO's Wegovy Cuts Heart Attack Risk
by Kinjel Shah
Eli Lilly (LLY), Bayer (BAYRY) and Novo Nordisk (NVO) announce second-quarter results.
Novo Nordisk (NVO) Q2 Earnings and Sales Miss, 2023 View Up
by Zacks Equity Research
Novo Nordisk (NVO) reports weaker-than-expected second-quarter 2023 results, missing both earnings and sales estimates. Management, however, raises 2023 guidance.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
Is Vanguard High Dividend Yield ETF (VYM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VYM
Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for HDV
The Zacks Analyst Blog Highlights PepsiCo, Johnson & Johnson, Intuitive Surgical, Kimberly-Clark and Atmos Energy
by Zacks Equity Research
PepsiCo, Johnson & Johnson, Intuitive Surgical, Kimberly-Clark and Atmos Energy are included in this Analyst Blog.
Halozyme (HALO) Q2 Earnings & Revenues Beat, 2023 View Raised
by Zacks Equity Research
Halozyme (HALO) shares rise 4% in the after-market trading hours on better-than-expected second-quarter 2023 results, boosted by collaboration and royalty revenues. Management raises its 2023 guidance.
Horizon (HZNP) Q2 Earnings Top, Krystexxa & Uplizna Boost Sales
by Zacks Equity Research
Horizon (HZNP) reports better-than-expected second-quarter results, beating both earnings and sales estimates, with the top-line key contributors being Krystexxa and Uplizna.
Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
Iovance (IOVA) reports mixed second-quarter results as earnings beat estimates but sales miss the mark.
Novavax (NVAX) Q2 Earnings Beat, Stock Down 4% on '23 Sales Cut
by Zacks Equity Research
Novavax (NVAX) reports better-than-expected Q2 earnings results, as earnings and revenues beat estimates. Shares drop due to lowered 2023 product sales guidance.
5 Defensive Stocks for Stable Returns Amid Recent Volatility
by Nalak Das
We have narrowed our search to five stocks from defensive sectors. These are: JNJ, PEP, ISRG, KMB, ATO.
Eli Lilly (LLY) Q2 Earnings Beat, Mounjaro Powers Sales Growth
by Zacks Equity Research
Eli Lilly (LLY) beats second-quarter estimates for earnings and sales. It raises its financial guidance for 2023.
Perrigo (PRGO) Beats on Q2 Earnings & Sales, Reiterates '23 View
by Zacks Equity Research
Perrigo (PRGO) reports encouraging second-quarter 2023 results. Management reaffirms the financial guidance for 2023.
CRISPR Therapeutics (CRSP) Q2 Loss Narrower Than Expected
by Zacks Equity Research
CRISPR Therapeutics' (CRSP) second-quarter results beat the mark for both earnings and sales.
Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) reports better-than-expected second-quarter 2023 results, beating both earnings and revenue estimates, primarily driven by the sales of its key dermatology products.